Todd A Alonzo Selected Research

Gemtuzumab (Mylotarg)

1/2024	Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group.
1/2022	A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
10/2021	Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
1/2019	ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
1/2019	CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
8/2017	CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
4/2016	Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
3/2016	CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
10/2015	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.
9/2014	Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Todd A Alonzo Research Topics

Disease

85	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2024 - 11/2002
21	Neoplasms (Cancer) 04/2024 - 11/2002
19	Leukemia 01/2023 - 05/2003
10	Infections 11/2016 - 11/2002
6	Residual Neoplasm 01/2022 - 06/2010
5	Neutropenia 01/2022 - 11/2002
4	Down Syndrome (Down's Syndrome) 01/2023 - 09/2003
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 07/2013
4	Myeloid Leukemia (Leukemia, Myelocytic) 07/2017 - 07/2002
2	Disease Progression 11/2023 - 10/2022
2	Lymphoma (Lymphomas) 11/2023 - 10/2022
2	Left Ventricular Dysfunction 01/2023 - 01/2020
2	Monosomy 01/2023 - 02/2014
2	Pain (Aches) 12/2022 - 05/2019
2	Acute Promyelocytic Leukemia 01/2022 - 09/2017
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 12/2011
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020 - 12/2010
2	Disseminated Intravascular Coagulation 01/2019 - 02/2009
2	monosomy Chromosome 7 01/2016 - 02/2014
2	Hepatomegaly 05/2004 - 05/2003
1	Septic Shock (Toxic Shock Syndrome) 11/2023
1	Brain Neoplasms (Brain Tumor) 11/2023
1	Trisomy (Trisomies) 01/2023
1	Cardiotoxicity 01/2023
1	Hemorrhage 12/2022
1	Glioma (Gliomas) 10/2022
1	Plexiform Neurofibroma 10/2022
1	Exanthema (Rash) 01/2022
1	Fever (Fevers) 01/2022
1	Typhlitis 01/2022
1	Hand-Foot Syndrome 01/2022
1	Necrosis 05/2019
1	Thrombosis (Thrombus) 01/2019
1	Alzheimer Disease (Alzheimer's Disease) 11/2016

Drug/Important Bio-Agent (IBA)

14	Gemtuzumab (Mylotarg)FDA Link 01/2024 - 05/2008
12	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 08/2003
8	Biomarkers (Surrogate Marker)IBA 01/2023 - 10/2008
6	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 08/2003
5	nuclear pore complex protein 98IBA 01/2023 - 10/2014
4	Bortezomib (Velcade)FDA Link 04/2024 - 10/2014
4	AnthracyclinesIBA 01/2023 - 08/2014
4	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2021 - 09/2003
3	CalicheamicinsIBA 01/2024 - 04/2016
3	Immunoconjugates (Immunoconjugate)IBA 11/2021 - 09/2014
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 11/2002
3	Messenger RNA (mRNA)IBA 01/2020 - 02/2011
3	LigandsIBA 12/2015 - 05/2011
2	Dexrazoxane (Zinecard)FDA LinkGeneric 01/2023 - 01/2020
2	A-Form DNA (A-DNA)IBA 01/2022 - 06/2007
2	Arsenic Trioxide (Trisenox)FDA Link 01/2022 - 09/2017
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 05/2013
2	MicroRNAs (MicroRNA)IBA 01/2020 - 12/2017
2	AntigensIBA 01/2020 - 02/2012
2	Dacarbazine (DIC)FDA LinkGeneric 01/2019 - 02/2009
2	Mitoxantrone (Novantrone)FDA LinkGeneric 10/2017 - 08/2003
2	MEF2 Transcription FactorsIBA 11/2016 - 10/2015
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 10/2014 - 01/2004
2	Clofarabine (Clolar)FDA Link 08/2014 - 07/2013
2	Thioguanine (Tioguanine)FDA Link 10/2012 - 09/2003
2	Dexamethasone (Maxidex)FDA LinkGeneric 10/2012 - 09/2003
2	Interleukin-2 (IL2)IBA 09/2011 - 06/2011
1	ChromatinIBA 04/2024
1	Proteasome InhibitorsIBA 04/2024
1	tazemetostatIBA 11/2023
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2023
1	Interleukin-10 (Interleukin 10)IBA 03/2023
1	Long Noncoding RNAIBA 01/2023
1	tetraiodothyroacetic acid (TA(4))IBA 12/2022
1	AZD 6244IBA 10/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2022
1	Mitogen-Activated Protein KinasesIBA 10/2022
1	A 17 (A-17)IBA 01/2022
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2022
1	triphosphoric acid (triphosphate)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	anetumab ravtansineIBA 11/2021
1	MesothelinIBA 11/2021
1	Lenalidomide (CC 5013)FDA Link 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	KIR ReceptorsIBA 01/2020
1	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	fludarabineIBA 01/2020
1	CPX-351IBA 01/2020
1	Cell Surface ReceptorsIBA 07/2017
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 07/2017
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2016

Therapy/Procedure

38	Therapeutics 04/2024 - 01/2002
37	Drug Therapy (Chemotherapy) 04/2024 - 09/2003
4	Induction Chemotherapy 12/2021 - 05/2004
4	Transplantation 01/2020 - 05/2003
4	Bone Marrow Transplantation (Transplantation, Bone Marrow) 12/2008 - 08/2003
3	Cryotherapy (Therapy, Cold) 12/2022 - 12/2010
2	Aftercare (After-Treatment) 12/2022 - 10/2014
2	Drug Tapering 01/2022 - 09/2017
2	Hematopoietic Stem Cell Transplantation 01/2020 - 01/2020
1	Molecular Targeted Therapy 10/2022
1	Hysterectomy 05/2019
1	Intravenous Administration 01/2017